中国肿瘤临床
中國腫瘤臨床
중국종류림상
CHINESE JOURNAL OF CLINICAL ONCOLOGY
2013年
2期
93-96
,共4页
马华玲%陈洪雷%朱润庆%郑明军%刘毓玲%范克非%杨为贵
馬華玲%陳洪雷%硃潤慶%鄭明軍%劉毓玲%範剋非%楊為貴
마화령%진홍뢰%주윤경%정명군%류육령%범극비%양위귀
肺鳞癌%Caveolin-1%预后
肺鱗癌%Caveolin-1%預後
폐린암%Caveolin-1%예후
lung squamous cell carcinoma%Caveolin-1%prognosis
目的:研究Caveolin-1在人肺鳞癌中的表达,探讨Caveolin-1的表达与人肺鳞癌临床病理特征以及预后的关系.方法:运用免疫组织化学法检测人肺鳞癌组织中Caveolin-1、PCNA的表达,并结合患者的临床病理特征和生存情况进行分析.结果:Caveolin-1在人肺鳞癌中阳性率显著低于正常肺组织(P<0.001);Caveolin-1的表达与肺鳞癌的TNM分期(P=0.018)及淋巴结状态(P=0.006)有关.在人肺鳞癌组织中Caveolin-1与PCNA表达呈正相关(r=0.360,P=0.018).生存分析显示肺鳞癌中Caveolin-1阳性组的生存时间显著低于阴性组(P=0.007),在24例淋巴结未转移组中Caveolin-1阳性组的生存时间显著低于阴性组(P=0.002).多因素Cox分析显示Caveolin-1阳性表达、高临床分期、支气管残端有癌残留的肺鳞癌患者术后生存时间较短.结论:Caveolin-1的表达与肺鳞癌的恶性演进呈正相关;其可促进肺癌细胞的增殖.Caveolin-1可作为评估肺鳞癌患者的不良预后指标.
目的:研究Caveolin-1在人肺鱗癌中的錶達,探討Caveolin-1的錶達與人肺鱗癌臨床病理特徵以及預後的關繫.方法:運用免疫組織化學法檢測人肺鱗癌組織中Caveolin-1、PCNA的錶達,併結閤患者的臨床病理特徵和生存情況進行分析.結果:Caveolin-1在人肺鱗癌中暘性率顯著低于正常肺組織(P<0.001);Caveolin-1的錶達與肺鱗癌的TNM分期(P=0.018)及淋巴結狀態(P=0.006)有關.在人肺鱗癌組織中Caveolin-1與PCNA錶達呈正相關(r=0.360,P=0.018).生存分析顯示肺鱗癌中Caveolin-1暘性組的生存時間顯著低于陰性組(P=0.007),在24例淋巴結未轉移組中Caveolin-1暘性組的生存時間顯著低于陰性組(P=0.002).多因素Cox分析顯示Caveolin-1暘性錶達、高臨床分期、支氣管殘耑有癌殘留的肺鱗癌患者術後生存時間較短.結論:Caveolin-1的錶達與肺鱗癌的噁性縯進呈正相關;其可促進肺癌細胞的增殖.Caveolin-1可作為評估肺鱗癌患者的不良預後指標.
목적:연구Caveolin-1재인폐린암중적표체,탐토Caveolin-1적표체여인폐린암림상병리특정이급예후적관계.방법:운용면역조직화학법검측인폐린암조직중Caveolin-1、PCNA적표체,병결합환자적림상병리특정화생존정황진행분석.결과:Caveolin-1재인폐린암중양성솔현저저우정상폐조직(P<0.001);Caveolin-1적표체여폐린암적TNM분기(P=0.018)급림파결상태(P=0.006)유관.재인폐린암조직중Caveolin-1여PCNA표체정정상관(r=0.360,P=0.018).생존분석현시폐린암중Caveolin-1양성조적생존시간현저저우음성조(P=0.007),재24례림파결미전이조중Caveolin-1양성조적생존시간현저저우음성조(P=0.002).다인소Cox분석현시Caveolin-1양성표체、고림상분기、지기관잔단유암잔류적폐린암환자술후생존시간교단.결론:Caveolin-1적표체여폐린암적악성연진정정상관;기가촉진폐암세포적증식.Caveolin-1가작위평고폐린암환자적불량예후지표.
Objective: This study aims to examine caveolin-1 expression in lung squamous cell carcinoma (LSCC), to investigate the relationship of caveolin-1 expression with clinicopathological features, and to estimate the prognostic value of caveolin-1. Methods:Immunohistochemical staining was used to determine caveolin-1 and PCNA expression in LSCC. The correlation among caveolin-1 ex-pression, pathological features, and clinical outcomes were investigated. Results: The positive rate of caveolin-1 protein was significantly lower in LSCC than in normal lung tissues (P<0.001). Caveolin-1 expression was statistically correlated with the TNM stage (P=0.018) and lymph node metastasis (P=0.006). Caveolin-1 expression was also positively correlated with PCNA expression in LSCC (r=0.360; P=0.018). The Kaplan–Meier survival curve showed that patients with positive caveolin-1 expression had a significantly shorter survival time compared with the patients with negative expression (P=0.007). The caveolin-1-positive group had a significantly shorter survival time in 24 patients without lymph node metastasis compared with the negative group (P=0.002). Cox multivariate analysis revealed that patients with caveolin-1 positive expression, high TNM stage, and positive surgical margin had a significantly unfavorable prognosis. Conclusion: Caveolin-1 expression is positively correlated with LSSC development as well as progression, and may promote tumor cell proliferation. Caveolin-1 may be used as a poor prognosis marker of LSCC.